Nanospectra Biosciences, Inc. develops and commercializes particle-based therapy devices for the selective and precise thermal destruction of solid tumors. The company’s portfolio includes AuroLase therapy that utilizes AuroShell particles/nanoshells, nanorods, and other nanomaterials for particle-based thermal ablation of solid tumors while minimizing damage to healthy adjacent tissue and preserving critical structures. The company was incorporated in 2001 and is based in Houston, Texas.